The NF-κB pathway has been reported to be especially relevant in inflammatory cancers, such as gastric and pancreatic cancers, where CBP/p300 inhibitors could potentially reduce NF-κB activity and suppress tumor-promoting inflammation. This evidence concerns the gene EP300 and neoplasm.